Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)

M. J. Overman, L. Adam, K. Raghav, J. Wang, B. Kee, D. Fogelman, C. Eng, E. Vilar, R. Shroff, A. Dasari, R. Wolff, J. Morris, Enusha Karunasena, T. R. Pisanic, N. Azad, S. Kopetz

Research output: Contribution to journalComment/debate

Abstract

In the original article, author T. R. Pisanic II's name was incorrectly spelt as 'R. Pisanic II'. This has now been corrected.

Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688)'. Together they form a unique fingerprint.

  • Cite this

    Overman, M. J., Adam, L., Raghav, K., Wang, J., Kee, B., Fogelman, D., Eng, C., Vilar, E., Shroff, R., Dasari, A., Wolff, R., Morris, J., Karunasena, E., Pisanic, T. R., Azad, N., & Kopetz, S. (2019). Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688). Annals of Oncology, 30(3). https://doi.org/10.1093/annonc/mdy221